Go to deals
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

Related deals

Laptaria cu Caimac has completed an IPO
Food & Beverage

Laptaria cu Caimac has completed an IPO

Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.

Learn more
Nutricare has raised US$3.1 million via an entitlement offer
Consumer & Retail | Healthcare

Nutricare has raised US$3.1 million via an entitlement offer

Nutricare Pty Ltd has raised funds to support its growth strategy.

Learn more
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Financial Services

Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland

Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.

Learn more